First-Line Therapy with Sunitinib in Advanced Renal Cell Carcinoma: Interpretation of the Overall Survival Data from ASCO 2008

Lori Wood

Abstract


 

Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor of VEGFR and PDGFR that has become a new standard of care in the management of metastatic renal cell carcinoma (RCC).  Motzer et al first presented the results of a pivotal, phase III, multi-centre trial in metastatic RCC comparing Sunitinib to Interferon alfa at ASCO 2006 and the data was subsequently published in January 20071,2. This study randomized previously untreated patients with metastatic clear cell carcinoma to either Sunitinib (50 mg once a day orally for 4 weeks followed by a 2-week break) or Interferon alfa (9 MU subcutaneously 3 times a week).  The primary endpoint was progression free-survival (PFS) and secondary endpoints included overall survival (OS), RECIST objective response rates, patient-reported outcomes and safety.


Full Text:

PDF


DOI: http://dx.doi.org/10.3747/co.v16i0.405






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)